Wart

Verrica Pharmaceuticals Announces Participation in the 21st Annual Needham Virtual Healthcare Conference

Retrieved on: 
Thursday, April 7, 2022
GLOBE, Company, Therapy, Molluscum contagiosum, Wart, Conference, Skin, Webcast, Dermatology, CEO, Pharmaceutical industry, Broadcasting

WEST CHESTER, Pa., April 07, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022 at 3:00 p.m.

Key Points: 
  • WEST CHESTER, Pa., April 07, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022 at 3:00 p.m.
  • Participants may access a live webcast of the event through the following link: https://wsw.com/webcast/needham117/vrca/2246788 .
  • The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com .
  • Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts.

Today's Podiatrist Keeps Kids Active

Retrieved on: 
Tuesday, April 5, 2022
DPMS, Association, Organization, Fracture, Podiatry, Emergency, APMA, ERS, DPM, Leg, Ankle, Disease, Nail, Sever's disease, Irritation, Pain, Injury, American Podiatric Medical Association, Shoe, Red, Wart, COVID-19, Basketball, Child, Sport, Eye, Education, Pacific Plate, Fatigue, Patient, Foot, Toy, Shoemaking, Parent

BETHESDA, Md., April 5, 2022 /PRNewswire/ -- America's podiatrists want parents to know that foot and ankle pain is never normal for kids. If a child experiences pain or a change in the condition of their feet and ankles, it's time to check in with the expert in kids' foot health—today's podiatrist.

Key Points: 
  • BETHESDA, Md., April 5, 2022 /PRNewswire/ -- America's podiatrists want parents to know that foot and ankle pain is never normal for kids.
  • If a child experiences pain or a change in the condition of their feet and ankles, it's time to check in with the expert in kids' foot healthtoday's podiatrist.
  • The Today's Podiatrist Keeps Kids Active campaign is designed to educate parents about how to keep their children's feet and ankles healthy and when to seek care from a podiatrist to ensure children can stay active.
  • Podiatrists say some of the most common conditions to watch for in kids are:
    ApophysitisIf a young athlete complains of persistent heel pain, it's time to see a podiatrist.

Verrica Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

Retrieved on: 
Tuesday, April 5, 2022
Mitochondrion, Private Securities Litigation Reform Act, Therapy, Skin, Bleeding, Squamous cell carcinoma, Pharmacokinetics, Clinical trial, Basal-cell carcinoma, Adult, Organelle, Research, Immunogenic cell death, Molluscum contagiosum, Program, Neoplasm, Incidence, Cancer, Dermatology, Pain, Skin cancer, WEST, Safety, Technology, Review, U.S. Securities and Exchange Commission, GLOBE, Scar, NDA, PDUFA, Wart, FDA, Patient, Infection, Vaccine, Pharmaceutical industry

WEST CHESTER, Pa., April 05, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the first patient has been dosed in the Company’s Phase 2 trial of LTX-315, a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma.

Key Points: 
  • While basal cell carcinoma is our lead indication for LTX-315, we also look forward to potentially expanding the program into squamous cell carcinoma in the future.
  • The study is expected to enroll approximately 66 adult subjects with a histological diagnosis of basal cell carcinoma in at least one eligible target lesion.
  • Basal cell carcinoma is the most common form of cancer in the U.S., and incidence is rising worldwide.
  • Basal cell carcinoma is generally treated with invasive surgery to remove the tumor, which can cause pain, infection, bleeding and scarring.

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 17, 2022
Mutation, PID, State Administrative Expenses, Conference, Risk, Pids, Immunoglobulin M, G&A, EDT, Lymphocyte, U.S. Securities and Exchange Commission, Severe congenital neutropenia, WHIM syndrome, SEC, R rating, Private Securities Litigation Reform Act, AACR, COVID-19, Medication, Wart, Forward-looking statement, Completeness, Clinical trial, Neutrophil, Research, Cancer, Immune system, Research and development, Genetic testing, Society, Oral, CIS, Conference call, Monocyte, Therapy, ASH, Security (finance), Prevalence, Clear cell renal cell carcinoma, Achievement, Disease, GLOBE, ID, Immunodeficiency, SCN, Safety, Adult, Axitinib, R, Biology, Pharmaceutical industry, Vaccine, Lithium, Infection, Hypogammaglobulinemia, CXCR4, Patient

BOSTON, March 17, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with diseases of the immune system, today reported financial results for the fourth quarter and twelve months ended December 31, 2021, and provided a corporate update.

Key Points: 
  • Top-line data from the 4WHIM trial are expected in the fourth quarter of 2022.
  • Cash, Cash Equivalents & Restricted Cash: X4 had $83.1 million in cash, cash equivalents, and restricted cash as of December 31, 2021.
  • The company expects that its cash and cash equivalents will fund company operations into the fourth quarter of 2022.
  • X4 will host a conference call and webcast today at 8:30 am EDT to discuss financial results and business highlights.

Emblation Announces Agreement with Specialist Medical Organisation Bo Medical for Exclusive Distribution of Swift® in the Netherlands, Belgium, and Luxembourg

Retrieved on: 
Monday, March 14, 2022
Aesthetics, Podiatry, HPV, Adoption, Wart, Internet, Hospital, Skin, Human papillomavirus infection, Patient, Technology, Invention, Medicine, Microwave, Pharmaceutical industry, Medical imaging, Healthcare, Swift, Dermatology, Benelux

EDINBURGH, Scotland, March 14, 2022 /PRNewswire-PRWeb/ --Emblation Limited, the global leader in medical microwave technology, is delighted to announce an agreement with Bo Medical, a specialist distributor of medical and aesthetic devices and products, for the exclusive distribution of Swift microwave therapy.

Key Points: 
  • EDINBURGH, Scotland, March 14, 2022 /PRNewswire-PRWeb/ --Emblation Limited, the global leader in medical microwave technology, is delighted to announce an agreement with Bo Medical, a specialist distributor of medical and aesthetic devices and products, for the exclusive distribution of Swift microwave therapy.
  • Alongside Calista Medical in Switzerland, the agreement with Bo Medical, based in the Netherlands, signals the launch of Swift in mainland Europe.
  • With treatment times in seconds, Swift provides Dermatologists and Podiatrists with a new, precise, and effective procedure for benign skin lesions.
  • Jonathan Williamson, Chief Commercial Officer of Emblation, commented, "We are really looking forward to launching Swift with Bo Medical.

Common Warts Market Insights, Epidemiology and Market Forecasts, 2032 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 14, 2022
Health, Pharmaceutical, Therapy, Common, News, Acquisition, Wart, Technology, Comprehension, Table, Management, Pharmaceutical industry, Epidemiology

The "Common Warts - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Common Warts - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's offering.
  • This "Common Warts- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Common Warts, historical and forecasted epidemiology as well as the Common Warts market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • The Common Warts epidemiology division provide insights about historical and current Common Warts patient pool and forecasted trend for every seven major countries.
  • Drug chapter segment of the Common Warts report encloses the detailed analysis of Common Warts marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.

Cassiopea SpA announces approval of delisting of its shares on SIX Swiss Exchange

Retrieved on: 
Saturday, March 5, 2022
Company, Acne, SKIN, AGA, SIX Swiss Exchange, Wart, Hair loss, MOA, Pharmaceutical industry, Fine chemical, Cassiopea

Cassiopea is a specialty pharmaceutical company developing and commercializing prescription drugs with novel mechanisms of action to address long-standing and essential dermatological conditions, particularly acne, androgenetic alopecia (or AGA) and genital warts.

Key Points: 
  • Cassiopea is a specialty pharmaceutical company developing and commercializing prescription drugs with novel mechanisms of action to address long-standing and essential dermatological conditions, particularly acne, androgenetic alopecia (or AGA) and genital warts.
  • Cassiopea is investing in innovation that is driving scientific advancement in areas that have been largely ignored for decades.
  • The portfolio comprises four unencumbered clinical candidates, for which Cassiopea owns the worldwide rights.
  • The Company's strategy is to leverage this expertise to optimize the commercial potential for its products with commercial partners.

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results

Retrieved on: 
Wednesday, March 2, 2022
NDA, Table, Control, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Dermatology, Research, Genetically modified bacteria, Patient, Pharmacokinetics, Adult, Immunotherapy, Food and Drug Administration, Food, Safety, Mission statement, U.S. Securities and Exchange Commission, Skin, Molluscum contagiosum, PDUFA, Silicon, FDA, New Drug Application, Collaboration, Wart, CMC, Company, WEST, Disease, Social stigma, Squamous cell carcinoma, Pain, Inflammation, Sibling, Cantharidin, GAAP, Private Securities Litigation Reform Act, Review, Silicon Valley Bank, Insurance, Fomite, Itch, Achievement, GLOBE, Therapy, Pharmaceutical industry, Bank, Animal, Reinsurance, Chemistry

WEST CHESTER, Pa., March 02, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the fourth quarter and year ended December 31, 2021.

Key Points: 
  • The amendment provides Verrica increased financial flexibility by extending the interest-only payment period and reducing the minimum cash Verrica is required to maintain on its balance sheet.
  • Verrica reported a net loss of $9.5 million for the fourth quarter of 2021, compared to a $13.0 million loss for the same period in 2020.
  • Research and development expenses were $3.4million in the fourth quarter of 2021, compared to $2.3 million for the same period in 2020.
  • General and administrative expenses were $5.1million in the fourth quarter of 2021, compared to $9.8 million for the same period in 2020.

Verrica Pharmaceuticals Announces Participation in the 42nd Annual Cowen Virtual Healthcare Conference

Retrieved on: 
Thursday, February 24, 2022
GLOBE, Skin, Therapy, Webcast, Wart, Dermatology, Company, Molluscum contagiosum, Conference, CEO, Pharmaceutical industry, Broadcasting

WEST CHESTER, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will participate in a fireside chat at the 42nd Annual Cowen Virtual Healthcare Conference on Wednesday, March 9, 2022, at 11:10 a.m.

Key Points: 
  • WEST CHESTER, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will participate in a fireside chat at the 42nd Annual Cowen Virtual Healthcare Conference on Wednesday, March 9, 2022, at 11:10 a.m.
  • Participants may access a live webcast of the event through the following link:
    The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com .
  • Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions.
  • Verrica is also developingVP-103,its second cantharidin-based product candidate, for the treatment of plantar warts.

ADVALight Brings The Gold Standard Laser Technology To St. Louis

Retrieved on: 
Wednesday, February 16, 2022
Hemangioma, Patient, Telangiectasia, Wart, Melasma, Greg Camp, Dermatology, Goal, Acne, Scar, Laser, Partnership, Rosacea, Dyschromia, Skin, Cosmetics, St. Louis

Travis Mahan, President of ADVALight shared, "We are thrilled to bring the ADVATx to St. Louis.

Key Points: 
  • Travis Mahan, President of ADVALight shared, "We are thrilled to bring the ADVATx to St. Louis.
  • We believe this partnership will allow Synergi Medspa to further enhance its reputation as one of St. Louis' go-tos for laser therapy treatments."
  • ADVATx from ADVALight combines the industry standard wavelength for eliminating vascular abnormalities with the new gold standard for non-ablative resurfacing to allow providers to treat 25 FDA/CE cleared indications ranging from vascular abnormalities to acne, wrinkle reduction, and warts.
  • Synergi Medspa is the first provider to offer ADVATx treatments in the St. Louis area and treatments will be available starting February 14, 2022.